logo
FPI selling, weak earnings drag equity markets to three-month lows

FPI selling, weak earnings drag equity markets to three-month lows

Indian equity benchmarks slumped on Monday, weighed down by stalled India-US trade talks, sustained foreign portfolio investor (FPI) selling, and sharp declines in
banking and IT heavyweights.
The Sensex plunged 572 points (0.7 per cent) to close at 80,891, while the Nifty fell 156 points (0.6 per cent )to 24,681. The selloff erased ₹3.8 trillion from the total market capitalisation of BSE-listed firms, now at ₹448 trillion. Monthly losses stand at ₹13.3 trillion, with both benchmarks down nearly 6 per cent from September peaks.
Investors were wary of taking positive bets amid reports that trade talks between India and the US remained deadlocked and dimmed hopes of an interim deal before US President Donald Trump's deadline. On the contrary, the deal between the US and EU eased concerns of a bigger trade tiff that could have hurt the global economy.
US President Donald Trump and European Commission President Ursula von der Leyen announced a trade deal on Sunday, which will see the bloc face 15 per cent tariffs on most of its exports.
FPIs were net sellers on Monday, worth approximately ₹ 6,083 crore, marking their sixth consecutive day of selling and the largest single-day sale since May 30.
Kotak Mahindra Bank was the largest contributor to the decline in the Sensex, followed by Bharti Airtel and Bajaj Finance. Kotak Mahindra Bank's shares declined 7.5 per cent, their biggest one-day fall since April 25, 2024, after the private lender posted a 40 per cent year–on–year (Y-o-Y) decline in its consolidated net profit to ₹4,472 crore in the April–June quarter.
A rise in provisions and contingencies due to higher slippages also weighed on profits for the recently concluded quarter.
TCS ended the session with a loss of 1.76 per after it announced on Sunday that it would lay off approximately
2 per cent, or around 12,260 employees, of its global workforce of 613,069 this financial year.
"Domestic market sentiment has remained cautious, weighed down by a disappointing set of Q1 earnings, delays in the India-US trade agreement, and continued FII outflows. In contrast, global markets remain broadly positive, supported by US-EU trade developments that are perceived as less concerning than anticipated,' said Vinod Nair, head of research of Geojit Investments.
In the future, the remainder of corporate earnings and the trajectory of the trade deal with the US will determine the market movement.
"Markets are currently grappling with headwinds on both domestic and global fronts. In the banking space, earlier resilience had helped limit the decline; however, renewed pressure across the sector — except for heavyweights ICICI Bank and HDFC Bank — is adding to participants' concerns. We now view the 24,450 – 24,550 zone as a critical support area, while the 24,900 – 25,000 range is likely to act as a resistance zone in case of a rebound. Traders should maintain a cautious stance and adjust their positions accordingly,' said Ajit Mishra, SVP-Research of Religare Broking.
Market breadth was weak with 2,951 declines and 1,200 advances.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Britannia Q1 profit misses estimates, sees early signs of urban recovery
Britannia Q1 profit misses estimates, sees early signs of urban recovery

Business Standard

time14 minutes ago

  • Business Standard

Britannia Q1 profit misses estimates, sees early signs of urban recovery

Britannia Industries posted first-quarter profit below estimates on Tuesday, but the Indian biscuit maker said urban consumption - dull for a few quarters - is picking up. The seller of 'Marie Gold' and 'Bourbon' biscuits joins other domestic consumer goods makers such as Hindustan Unilever and ITC in forecasting early signs of a recovery in urban demand, aided by easing local inflation. India's annual retail inflation slowed every month in the quarter, easing to a six-year low in June at 2.1 per cent. That helped spur a "marginal uptick in consumption across both urban and rural markets," said Varun Berry, managing director and chief executive. Britannia's quarterly sales grew 9.8 per cent to ₹4,535 crore ($516.5 million). The firm had previously flagged rise in popular demand for packaged food and confectionery items such as croissants, wafers and flavoured shakes - usually more likely to be bought on impulse. But total spends rose 10.4 per cent, led by a 15 per cent jump in raw material costs. Britannia has been hiking prices to partly offset the higher costs of raw materials such as cocoa, flour and palm oil. Profits in the reported quarter came in at ₹521 crore, up 3 per cent on-year, but below analysts' average estimate of ₹570 crore rupees, according to data compiled by LSEG.

Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26

Business Standard

time14 minutes ago

  • Business Standard

Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26

Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.

P B Balaji, a CFO who plays with a straight bat, now captains JLR
P B Balaji, a CFO who plays with a straight bat, now captains JLR

Business Standard

time14 minutes ago

  • Business Standard

P B Balaji, a CFO who plays with a straight bat, now captains JLR

Balaji's rise to the top spot at JLR as its CEO comes at a time when the company is in a transition phase, lining up plans for more electric vehicles Shine Jacob Chennai Listen to This Article His career moves across the world — from countries like Switzerland and Singapore to cities like London — meant his daughter had to switch nine schools in just 15 years. This is just one glimpse into the lesser-known personal side of the otherwise career-oriented Pathamadai Balachandran Balaji, who was elevated as the first Indian chief executive officer of Tata Motors-owned luxury carmaker Jaguar Land Rover (JLR) on Monday. However, his life is about more than just boardroom talks and business growth. Balaji, in his mid-50s, is a die-hard cricket enthusiast and an admirer of Virat Kohli, yet chooses not to

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store